share_log

HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $18 Price Target

Benzinga ·  Aug 14 18:55  · Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $18 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment